Ignite Creation Date:
2024-05-05 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00150800
Status:
COMPLETED
Last Update Posted:
2021-08-17
First Post:
2005-09-06
Brief Title:
This Trial Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy Who May Have Benefited From Brivaracetam as Adjunctive Treatment the Opportunity to Receive Open Label Brivaracetam Treatment
Sponsor:
UCB PHARMA Inc US
Organization:
UCB Pharma
Study Overview
Official Title:
An Open-label Multi-center Follow-up Trial to Evaluate Long Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 200 mgDay in Subjects Aged 16 Years or Older Suffering From Epilepsy
Status:
COMPLETED
Status Verified Date:
2021-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
NCT03532516
Has Expanded Access, NCT# Status:
AVAILABLE
Acronym:
None
Brief Summary:
This trial evaluating the long-term safety and tolerability of brivaracetam will provide subjects suffering from epilepsy who may have benefited from brivaracetam as adjunctive treatment the opportunity to receive open label brivaracetam treatment
Detailed Description:
Study access was limited to subjects having completed one of the previous brivaracetam BRV studies N01193 NCT00175825 N01252 NCT00490035 N01253 NCT00464269 N01254 NCT00504881
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None